Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of
HDSD daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- SSP for
7-14 days) in patients with cSSSI due to Gram-positive bacteria. Patients will be randomized
on a 1:1 basis to receive either daptomycin 10 mg/kg i.v. q24h for 4 days or vancomycin 1 g.
q12h for up to 14 days.